# FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT05011188** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rahul Aggarwal** · enrollment: 44 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** FOR46
- **BIOLOGICAL:** Enzalutamide
- **DRUG:** Pegfilgrastim
- **PROCEDURE:** Blood Samples

## Key facts

- **NCT ID:** NCT05011188
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-19
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2025-08-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011188, "FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05011188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*